VILIP-1 downregulation in non-small cell lung carcinomas: Mechanisms and prediction of survival

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Fu, Jian ^a   Fong, Kathryn ^a   Bellacosa, Alfonso ^a   Ross, Eric ^a   Apostolou, Sinoula ^a   Bassi, Daniel E ^a   Jin, Fang ^a   Zhang, Jirong ^a   Cairns, Paul ^a   de Caceres, Inmaculada Ibañez ^a   Braunewell, Karl Heinz ^b   Klein Szanto, Andres J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; NEURONAL CALCIUM SENSOR; TRICHOSTATIN A; VISININ LIKE PROTEIN 1; NEUROCALCIN; VSNL1 PROTEIN, HUMAN;

ACETYLATION; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA CELL; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DOWN REGULATION; EXPERIMENTAL ANIMAL; GENE DELETION; GENE LOSS; GENE MUTATION; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PREDICTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; SURVIVAL RATE;

ANIMALIA;

CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; NEUROCALCIN; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SURVIVAL RATE;

EID: 45949096014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001698     Document Type: Article

References (37)

1. Braunewell KH (2005) The darker side of Ca2+ signaling by neuronal Ca2+-sensor proteins: from Alzheimer's disease to cancer. Trends Pharmacol Sci 26: 345-351.
2. Burgoyne RD, Weiss JL (2001) The neuronal calcium sensor family of Ca2+-binding proteins. Biochem J 353: 1-12.
3. Mahloogi H, Gonzalez-Guerrico AM, Lopez De Cicco R, Bassi DE, Goodrow T, et al. (2003) Overexpression of the calcium sensor visinin-like protein-1 leads to a cAMP-mediated decrease of in vivo and in vitro growth and invasiveness of squamous cell carcinoma cells. Cancer Res 63: 4997-5004.
4. Gonzalez Guerrico AM, Jaffer ZM, Page RE, Braunewell KH, Chernoff J, et al. (2005) Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene 24: 2307-2316.
5. Wickborn C, Klein-Szanto AJ, Schlag PM, Braunewell KH (2006) Correlation of visinin-like-protein-1 expression with clinicopathological features in squamous cell carcinoma of the esophagus. Mol Carcinog 45: 572-581.
6. Fin J, Chen Y, Chan HM, Tam PK, Ren Y (2005) Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells. Proc Natl Acad Sci U S A 102: 17751-17756.
7. Osada H, Takahashi T (2002) Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21: 7421-7434.
8. Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717.
9. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. (2004) Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 114: 146-1157.
10. Gairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, et al. (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7: 2727-2730.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
12. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997.
13. Luo RX, Postigo AA, Dean DC (1998) Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473.
14. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
15. Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
16. Davuluri RV, Grosse I, Zhang MQ (2001) Computational identification of promoters and first exons in the human genome. Nat Genet 29: 412-417.
17. Prestridge DS (1995) Predicting Pol II promoter sequences using transcription factor binding sites. J Mol Biol 249: 923-932.
18. Knudsen S (1999) Promoter2.0: for the recognition of PolII promoter sequences. Bioinformatics 15: 356-361.
19. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, et al. (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 15: 1034-1050.
20. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
21. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196: 261-282.
22. Santos-Rosa H, Caldas C (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41: 2381-2402.
23. Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26: 1481-1487.
24. Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell, 1: 49-52.
25. Gierke P, Zhao C, Brackmann M, Linke B, Heinemann U, et al. (2004) Expression analysis of members of the neuronal calcium sensor protein family: combining bioinformatics and Western blot analysis. Biochem Biophys Res Commun 323: 38-43.
26. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, et al. (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23: 6569-6580.
27. Deng XY, Cai F, Xia K, Pan Q, Long ZG, et al. (2005) Identification of the alternative promoters of the KCh1P4 subfamily. Acta Biochim Biophys Sin (Shanghai) 37: 241-247.
28. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116.
29. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
30. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165.
31. Rice JC, Allis CD (2001) Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 13: 263-273.
32. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, et al. (2001) Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61: 8331-8339.
33. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, et al. (2003) Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9: 3034-3041.
34. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98: 396-406.
35. Tani M, Ito J, Nishioka M, Kohno T, Tachibana K, et al. (2004) Correlation between histone acetylation and expression of the MYO18B gene in human lung cancer cells. Genes Chromosomes Cancer 40: 146-151.
36. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333.
37. Zhong S, Fields CR, Su N, Pan YX, Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621-2634.